Tenax Therapeutics (TENX) Set to Release Earnings on Wednesday

Tenax Therapeutics (NASDAQ:TENX) is projected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Tenax Therapeutics Stock Performance

Shares of TENX opened at $1.84 on Wednesday. The firm has a market cap of $68.85 million, a P/E ratio of -1.24 and a beta of 0.99. Tenax Therapeutics has a twelve month low of $1.31 and a twelve month high of $19.40. The firm’s 50 day moving average price is $1.84 and its two-hundred day moving average price is $9.96.

Analyst Ratings Changes

A number of brokerages recently weighed in on TENX. Wall Street Zen lowered shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tenax Therapeutics in a research note on Thursday, September 10th. UBS Group lowered Tenax Therapeutics to a “neutral” rating in a report on Monday, August 31st. William Blair cut Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $14.00.

Insiders Place Their Bets

In other Tenax Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 331,979 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was acquired at an average price of $1.66 per share, with a total value of $551,085.14. Following the completion of the transaction, the insider owned 7,447,000 shares in the company, valued at approximately $12,362,020. This trade represents a 4.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Declan Doogan purchased 53,000 shares of the stock in a transaction on Wednesday, September 16th. The stock was acquired at an average price of $1.92 per share, for a total transaction of $101,760.00. Following the completion of the purchase, the director directly owned 55,274 shares in the company, valued at approximately $106,126.08. The trade was a 2,330.69% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 3,682,899 shares of company stock worth $6,388,279. 10.81% of the stock is currently owned by insiders.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.